Fortrea Holdings (FTRE) Aandelenoverzicht
Fortrea Holdings Inc., een organisatie voor contractonderzoek, biedt oplossingen voor de ontwikkeling van biofarmaceutische producten en medische hulpmiddelen aan farmaceutische, biotechnologische en medische klanten over de hele wereld. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
FTRE Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortrea Holdings Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$17.91 |
| 52 Week Hoogtepunt | US$18.67 |
| 52 Week Laag | US$4.93 |
| Bèta | 2.01 |
| 1 maand verandering | 16.98% |
| 3 maanden verandering | 70.57% |
| 1 Jaar Verandering | 208.79% |
| 3 jaar verandering | -46.93% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -40.50% |
Recent nieuws en updates
Narratiefupdate • Jul 14
FTRE: Steady Utilization And Execution Risks Will Restrain Future Share Upside
Fortrea Holdings' analyst price target has moved higher, with recent updates pointing to a range of $16 to $18 as analysts factor in steadier healthcare utilization trends and more supportive sentiment toward life science tools in their forecasts. Analyst Commentary Recent research updates on Fortrea Holdings show price targets consolidating in the mid-teens, with most commentary linked to broader readthroughs from healthcare utilization surveys and sentiment toward life science tools rather than company specific catalysts.
Narratiefupdate • Jun 22
FTRE: Execution On 2026 Guidance And AI Rollout Will Shape Risk Reward
Fortrea Holdings' updated analyst price target has moved higher to $16.21 from $14.44. This reflects analysts' use of a lower discount rate, slightly stronger assumptions for revenue growth and profit margins, and a modestly higher future P/E multiple supported by a series of recent target increases across major firms.Recent updates
Narratiefupdate • Jul 14
FTRE: Steady Utilization And Execution Risks Will Restrain Future Share Upside
Fortrea Holdings' analyst price target has moved higher, with recent updates pointing to a range of $16 to $18 as analysts factor in steadier healthcare utilization trends and more supportive sentiment toward life science tools in their forecasts. Analyst Commentary Recent research updates on Fortrea Holdings show price targets consolidating in the mid-teens, with most commentary linked to broader readthroughs from healthcare utilization surveys and sentiment toward life science tools rather than company specific catalysts.Narratiefupdate • Jun 22
FTRE: Execution On 2026 Guidance And AI Rollout Will Shape Risk Reward
Fortrea Holdings' updated analyst price target has moved higher to $16.21 from $14.44. This reflects analysts' use of a lower discount rate, slightly stronger assumptions for revenue growth and profit margins, and a modestly higher future P/E multiple supported by a series of recent target increases across major firms.Narratiefupdate • Jun 08
FTRE: Ongoing Execution Risks Around 2026 Guidance Will Limit Upside Potential
Analysts have lifted their aggregate price target on Fortrea Holdings by several dollars to reflect updated assumptions for revenue growth, margins and future P/E expectations, following a series of recent target increases from major firms. Analyst Commentary Recent research on Fortrea reflects a mix of optimism and caution, with some firms lifting price targets and others trimming their expectations as they reassess the stock's risk and reward trade off.
Narratiefupdate • May 25
FTRE: Conservative 2026 Guidance And AI Tools May Drive Re Rating
Analysts raised Fortrea Holdings’ fair value estimate to $20.00 from $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E that are consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research around Fortrea has shifted toward a more constructive tone, with several bullish analysts lifting price targets and one firm moving the stock to a higher rating category.Narratiefupdate • May 07
FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside
Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.Narratiefupdate • Apr 21
FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating
The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.Narratiefupdate • Apr 07
FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating
Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.Narratiefupdate • Mar 24
FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.Narratiefupdate • Mar 09
FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside
The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.Narratiefupdate • Feb 23
FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.Analyse-artikel • Feb 12
The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%
Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have retraced a considerable 33% in the last month, reversing a fair...Narratiefupdate • Feb 09
FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside
Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.Narratiefupdate • Jan 25
FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating
Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.Narratiefupdate • Jan 11
FTRE: New Leadership And Margin Recovery Path May Drive Re Rating
Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.Narratiefupdate • Dec 27
FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks
Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.Narratiefupdate • Dec 13
FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution
Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.Analyse-artikel • Dec 07
Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have been powering on, with a gain of 27...Narratiefupdate • Nov 29
FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends
Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.Seeking Alpha • Nov 20
Fortrea Holdings: Showing Real Signs Of Life
Summary Fortrea Holdings has shown signs of recovery after severe operational and financial struggles, with shares rebounding from historic lows. The company reported improving sales momentum and a rising backlog, but EBITDA and margins remain under pressure, keeping leverage high. Management has implemented cost reductions, raised guidance, and enacted a shareholder rights plan, signaling renewed urgency and insider confidence. While the darkest scenarios seem less likely, conviction to buy remains low; continued monitoring is warranted as recovery progresses. Read the full article on Seeking AlphaNarratiefupdate • Nov 15
FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026
Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.Narratiefupdate • Nov 01
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.Narratiefupdate • Oct 18
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.Narratiefupdate • Oct 03
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.Narratiefupdate • Sep 05
Global Demographic Trends Will Spur Clinical Advances
The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.Analyse-artikel • Aug 14
Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?
NasdaqGS:FTRE 1 Year Share Price vs Fair Value Explore Fortrea Holdings's Fair Values from the Community and select...Narratiefupdate • Aug 07
Global Demographic Trends Will Spur Clinical Advances
Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.Analyse-artikel • Jun 21
Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching
Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...Nieuw narratief • May 17
New Therapeutic Areas And AI Adoption Will Fuel Progress
Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.Analyse-artikel • May 08
Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?
Key Insights Fortrea Holdings' estimated fair value is US$11.03 based on 2 Stage Free Cash Flow to Equity Fortrea...Analyse-artikel • Apr 08
Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Mar 06
Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Summary FTRE's strong backlog of $7.7 billion provides revenue stability and planning advantages, despite short-term spin-off costs and missed earnings. The CRO market is projected to grow significantly, driven by increased outsourcing of complex late-stage trials, positioning FTRE for long-term growth. FTRE's global reach across 90 countries offers a competitive advantage in multi-region trials, enhancing patient enrollment and administrative efficiency. Post-spin-off, FTRE can focus on high-margin areas like oncology and decentralized trials, with expected margin improvements from reduced overhead costs. Read the full article on Seeking AlphaAnalyse-artikel • Mar 04
Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet
To the annoyance of some shareholders, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares are down a considerable 38% in the...Rendement voor aandeelhouders
| FTRE | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -0.7% | -3.9% | -0.7% |
| 1Y | 208.8% | 14.8% | 17.3% |
Rendement versus industrie: FTRE overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 14.8 % opleverde.
Rendement versus markt: FTRE overtrof de US markt, die het afgelopen jaar een rendement opleverde van 17.3 %.
Prijsvolatiliteit
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 9.7% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: FTRE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van FTRE is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2023 | 14,000 | Anshul Thakral | www.fortrea.com |
Fortrea Holdings Inc., een organisatie voor contractonderzoek, biedt oplossingen voor de ontwikkeling van biofarmaceutische producten en medische apparatuur aan farmaceutische, biotechnologische en medische klanten wereldwijd. Het biedt klinische farmacologie, zoals klinische onderzoekseenheden, externe partnerschappen, projectmanagement, studieontwerp en -bewaking, bioanalyse en biomarkers, farmacokinetiek, modellering en simulatie, en biometrie; en klinische ontwikkeling, waaronder fase I tot en met IV klinische en real-world evidence studies, regelgevingszaken, protocolontwerp, operationele planning, het opstarten van studies en locaties, patiëntenwerving, projectmanagement, uitgebreide locatie- en medische bewaking, gegevensbeheer en biostatistiek, geneesmiddelenbewaking, medisch schrijven en mobiele klinische diensten. Het bedrijf levert ook adviesdiensten op het gebied van productontwikkeling en regelgeving, markttoegang en gezondheidseconomie, en uitkomstenonderzoek, evenals RWE-diensten.
Fortrea Holdings Inc. Samenvatting
| FTRE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.68b |
| Inkomsten(TTM) | -US$446.90m |
| Inkomsten(TTM) | US$2.71b |
0.6x
P/S-verhouding-3.8x
Koers/WinstverhoudingIs FTRE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| FTRE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.71b |
| Kosten van inkomsten | US$2.20b |
| Brutowinst | US$510.90m |
| Overige uitgaven | US$957.80m |
| Inkomsten | -US$446.90m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 29, 2026
| Winst per aandeel (EPS) | -4.72 |
| Brutomarge | 18.86% |
| Nettowinstmarge | -16.50% |
| Schuld/Eigen Vermogen Verhouding | 200.4% |
Hoe presteerde FTRE op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/21 14:02 |
| Aandelenkoers aan het einde van de dag | 2026/07/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Fortrea Holdings Inc. wordt gevolgd door 13 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |